Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-23-031168
Filing Date
2023-11-09
Accepted
2023-11-09 13:55:22
Documents
55
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q inbp20230930_10q.htm   iXBRL 10-Q 773383
2 EXHIBIT 31.1 CERTIFICATION OF CO-CEOS ex_571717.htm EX-31.1 13554
3 EXHIBIT 31.2 CERTIFICATION OF CFO ex_571718.htm EX-31.2 15164
4 EXHIBIT 32.1 CERTIFICATION OF CO-CEOS PURSUANT TO 18 USC ex_571719.htm EX-32.1 9109
5 EXHIBIT 32.2 CERTIFICATION OF CFO PURSUANT TO 18 USC ex_571720.htm EX-32.2 7182
  Complete submission text file 0001437749-23-031168.txt   4562136

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA inbp-20230930.xsd EX-101.SCH 43601
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE inbp-20230930_cal.xml EX-101.CAL 37794
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE inbp-20230930_def.xml EX-101.DEF 308377
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE inbp-20230930_lab.xml EX-101.LAB 266907
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inbp-20230930_pre.xml EX-101.PRE 326047
49 EXTRACTED XBRL INSTANCE DOCUMENT inbp20230930_10q_htm.xml XML 673409
Mailing Address 225 LONG AVENUE BUILDING 15 HILLSIDE NJ 07205
Business Address 225 LONG AVENUE BUILDING 15 HILLSIDE NJ 07205 9739260816
INTEGRATED BIOPHARMA INC (Filer) CIK: 0001016504 (see all company filings)

EIN.: 222407475 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-31668 | Film No.: 231391660
SIC: 2834 Pharmaceutical Preparations